Current Study: Combined Behavioral and Analgesic Trial for Fibromyalgia (COMBAT-FM)
The Combined Behavioral and Analgesic Trial for Fibromyalgia studies ways to improve the lives of those who live with Fibromyalgia
Fibromyalgia (FM) is a chronic widespread pain syndrome. The cause is unknown, and there is currently no treatment that cures it.
One of the most frustrating problems of FM is that others cannot see or feel the pain and other symptoms that you are experiencing. There are no outward signs that indicate how much pain and fatigue you feel. Even when you feel terrible, family or friends may remark about how well you look. Thus, FM can be described as an invisible, ongoing nightmare that others cannot see or feel. Being trapped in this nightmare may cause you to doubt your own sanity, make you feel more depressed, or lead you to withdraw from other people.
FM is often referred to as a woman’s illness because 75 to 85 percent of the people who receive the diagnosis are women. The truth is, however, it does affect millions of people, and anyone (including men and children) can get it. Also, FM is a worldwide problem, rather than one that occurs just in the United States. It is estimated that 5% of the world’s population has FM and that millions of people remain undiagnosed.
Combined Behavioral and Analgesic Trial for Fibromyalgia (COMBAT-FM)
Since no single treatment has been found to be totally effective in treating people with FM, we are studying the effects of combinations of treatments. Our study involves the combination of different behavioral health and drug treatments. We plan to evaluate different combinations of these treatments for people with FM, to see which ones work best and for whom. Participants in this study will be randomly assigned (by chance) to a group. Some participants will receive the study medication and others will receive placebo pills (inactive substance).
Men and women ages 21 to 70 who meet the following requirements may be included in this study (there are some additional requirements that may limit your treatment in the study).
Participants may be included who:
Participation in the study involves 13 total visits over 15 weeks with a follow up visit 6 months after completion of treatment.
There is no charge for these evaluations or treatments. This study is supported by a grant from the National Institutes of Health (NIH) to evaluate the combination of drug and behavioral health treatments for people with FM.
Those who participate may be paid up to $300.00 for their time and effort.
All evaluations and treatments will be held at:
University District Building
1107 Northeast 45th Street, Suite 320
Seattle WA 98105
If you would like to participate or would like to learn more information about our current study, please contact us at (206)221-1737 or firstname.lastname@example.org.